Guardant Health Inc (GH) - Total Liabilities
Based on the latest financial reports, Guardant Health Inc (GH) has total liabilities worth $2.10 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guardant Health Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Guardant Health Inc's total liabilities have evolved over time, based on quarterly financial data. See GH net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Guardant Health Inc Competitors by Total Liabilities
The table below lists competitors of Guardant Health Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
COLOPLAST SP.ADR 1/10 DK1
F:CBH
|
Germany | €34.99 Billion |
|
Logitech International S.A.
SW:LOGN
|
Switzerland | CHF1.64 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
Germany | €5.23 Billion |
|
Hubei Dinglong Chemical
SHE:300054
|
China | CN¥3.97 Billion |
|
Wolters Kluwer N.V.
AS:WKL
|
Netherlands | €8.79 Billion |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
China | CN¥11.08 Billion |
|
Check Point Software Technologies Ltd
NASDAQ:CHKP
|
USA | $4.80 Billion |
|
Permian Resources Corporation
NYSE:PR
|
USA | $6.05 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Guardant Health Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guardant Health Inc (GH) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guardant Health Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guardant Health Inc (2016–2025)
The table below shows the annual total liabilities of Guardant Health Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.11 Billion | +30.01% |
| 2024-12-31 | $1.63 Billion | -0.15% |
| 2023-12-31 | $1.63 Billion | +5.03% |
| 2022-12-31 | $1.55 Billion | -0.62% |
| 2021-12-31 | $1.56 Billion | +70.22% |
| 2020-12-31 | $916.19 Million | +699.87% |
| 2019-12-31 | $114.54 Million | +83.41% |
| 2018-12-31 | $62.45 Million | +81.90% |
| 2017-12-31 | $34.33 Million | -6.88% |
| 2016-12-31 | $36.87 Million | -- |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more